Medial EarlySign’s AI-driven machine learning solutions empower healthcare stakeholders to keep patients healthier for extended periods. The company’s advanced models derive actionable clinical insights from massive datasets, helping improve patient outcomes, optimize diagnostics, and enhance medication management. Medial EarlySign's purpose-built development environment ensures precision decision-making, supported by peer-reviewed studies published by leading healthcare organizations worldwide. EarlySign helps clients identify people at high risk for conditions such as non-small cell lung cancer (NSCLC), lower GI disorders and cancers, prediabetic progression to diabetes, downstream diabetic complications, risk for flu and its complications, chronic kidney disease (CKD), COVID-19, and more. The company was named a cool vendor in "Cool Vendors in AI for Healthcare, 2017" by the Gartner Research Group and was a winner of the CMS AI Health Outcomes Challenge.